KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CareDx (CDNA) Cash & Equivalents: 2013-2025

Historic Cash & Equivalents for CareDx (CDNA) over the last 13 years, with Sep 2025 value amounting to $91.4 million.

  • CareDx's Cash & Equivalents fell 4.16% to $91.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.4 million, marking a year-over-year decrease of 4.16%. This contributed to the annual value of $114.7 million for FY2024, which is 39.53% up from last year.
  • Latest data reveals that CareDx reported Cash & Equivalents of $91.4 million as of Q3 2025, which was up 34.05% from $68.2 million recorded in Q2 2025.
  • Over the past 5 years, CareDx's Cash & Equivalents peaked at $353.1 million during Q3 2021, and registered a low of $68.2 million during Q2 2025.
  • Its 3-year average for Cash & Equivalents is $88.0 million, with a median of $88.7 million in 2025.
  • Per our database at Business Quant, CareDx's Cash & Equivalents soared by 860.90% in 2021 and then slumped by 76.50% in 2022.
  • Quarterly analysis of 5 years shows CareDx's Cash & Equivalents stood at $348.5 million in 2021, then plummeted by 74.20% to $89.9 million in 2022, then dropped by 8.59% to $82.2 million in 2023, then skyrocketed by 39.53% to $114.7 million in 2024, then declined by 4.16% to $91.4 million in 2025.
  • Its Cash & Equivalents was $91.4 million in Q3 2025, compared to $68.2 million in Q2 2025 and $88.7 million in Q1 2025.